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BACKGROUND AND PURPOSE
Numerous claims are made for cannabis’ therapeutic utility upon human seizures, but concerns persist about risks. A potential
confounder is the presence of both Δ9-tetrahydrocannabinol (THC), variously reported to be pro- and anticonvulsant, and
cannabidiol (CBD), widely conﬁrmed as anticonvulsant. Therefore, we investigated effects of prolonged exposure to different
THC/CBD cannabis extracts on seizure activity and associated measures of endocannabinoid (eCB) system signalling.
EXPERIMENTAL APPROACH
Cannabis extract effects on in vivo neurological and behavioural responses, and on bioanalyte levels, were measured in rats and
dogs. Extract effects on seizure activity were measured using electroencephalography telemetry in rats. eCB signalling was also
investigated using radioligand binding in cannabis extract-treated rats and treatment-naïve rat, mouse, chicken, dog and human
tissue.
KEY RESULTS
Prolonged exposure to cannabis extracts caused spontaneous, generalized seizures, subserved by epileptiform discharges in rats,
but not dogs, and produced higher THC, but lower 11-hydroxy-THC (11-OH-THC) and CBD, plasma concentrations in rats versus
dogs. In the same rats, prolonged exposure to cannabis also impaired cannabinoid type 1 receptor (CB1 receptor)-mediated
signalling. Proﬁling CB1 receptor expression, basal activity, extent of activation and sensitivity to THC suggested interspecies
differences in eCB signalling, being more pronounced in a species that exhibited cannabis extract-induced seizures (rat) than one
that did not (dog).
CONCLUSIONS AND IMPLICATIONS
Sustained cannabis extract treatment caused differential seizure, behavioural and bioanalyte levels between rats and dogs.
Supporting radioligand binding data suggest species differences in eCB signalling. Interspecies variations may have important
implications for predicting cannabis-induced convulsions from animal models.
Abbreviations
CBD, cannabidiol; EEG, electrocorticography; eCB, endocannabinoid; PCA, principal component analysis; PSD, power
spectrum density; THC, Δ9-tetrahydrocannabinol
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Introduction
Recent legal and regulatory change in the USA and elsewhere
has increased awareness, and use of, cannabis (marijuana) for
recreational and potential medicinal purposes, including
treatment-resistant paediatric epilepsies (Devinsky et al.,
2014; 2015). Such cannabis preparations typically contain
signiﬁcant amounts of Δ9-tetrahydrocannabinol (THC),
a high potency, low intrinsic efﬁcacy, CB1 receptor partial
agonist; however, there is little evidence of THC efﬁcacy or
safety in epilepsy (Press et al., 2015). Moreover, reports are
tempered by psychiatric complications of cannabis in adoles-
cents (Volkow et al., 2014) and medical and psychiatric emer-
gencies, including seizures and mortality, among recreational
users of novel synthetic CB1 receptor high intrinsic efﬁcacy
agonists (Castaneto et al., 2014; Gurney et al., 2014). Short-
term exposure to CB1 receptor partial or full agonists typically
exerts anticonvulsant effects in animal models of seizure and
epilepsy (Rosenberg et al., 2015). By contrast, sustained THC
administration is reported to cause convulsions in rats and
mice (Chan et al., 1996; NTP, 1996) and, anecdotally,
chickens. The other most common cannabinoid, cannabidiol
(CBD), is not psychoactive, is widely conﬁrmed as anticon-
vulsant in animal models of seizure and epilepsy and lacks re-
ported proconvulsant effects (Rosenberg et al., 2015). CBD
reduces convulsive seizures in children and young adults
with Dravet syndrome and with Lennox–Gastaut syndrome
(Devinsky et al., 2016; 2017). A meta-analysis found that
CBD behavioural pharmacology is unrelated to direct effects
at CB1 receptors (McPartland et al., 2015), although indirect
CBD effects on the endocannabinoid (eCB) system, as well
as negative allosteric modulation of CB1 receptors in vitro
(Laprairie et al., 2015) have been reported; rather, CBD has
several potential non-CB1 receptor-mediated actions (Hill
et al., 2012).
Despite this knowledge, it remains unknown whether
sustained cannabis-induced convulsions are spontaneous
and/or epileptiform in nature, with reports of both de-
pressed and enhanced epileptogenesis in animal models
(Rosenberg et al., 2017). Moreover, no relationship between
convulsion incidence and other aberrant behaviours has
been established. The extent to which changes in eCB sig-
nalling that may be involved in cannabis-induced convul-
sions in rodents are recapitulated in other species also
remains to be elucidated. With these points in mind, we
examined the effects of standardized extracts containing
different doses of THC and CBD on in vivo behaviour and
seizure activity in rats and dogs, species reportedly prone
and resistant to cannabis-induced seizure respectively. We
demonstrate for the ﬁrst time that prolonged exposure to
cannabis extracts produces dose-related motor convulsions
subserved by epileptiform activity and associated seizure-
related behaviours in rats. By contrast, cannabis extracts
never caused seizures in dogs, which exhibited reduced
THC but higher 11-OH-THC and CBD plasma concentra-
tions than rats. Across several species, the eCB system sig-
nalling proﬁle was highest in the rat but lowest in the
dog. These data clarify several apparent inconsistencies in
the ﬁeld and suggest that choice of model species has im-
portant implications in the study of cannabis-induced
convulsions.
Methods
Animals
Animal studies are reported in compliance with the ARRIVE
guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015).
Rodent behavioural studies were conducted under contract
by Covance Laboratories Ltd (Leeds, UK) according to the au-
thors’ experimental design and in accordance with the UK
Animals (Scientiﬁc Procedures) Act 1986. Sixty-nine adult
(240–280 g at study start) female Wistar–Han rats were used.
Female rats were used here since they are reported to have
an increased frequency of THC-induced convulsions com-
pared to male rats (NTP, 1996). Rats, habituated for 16 days
prior to the start of any experimental procedures, were singly
housed in standard laboratory cages with environmental en-
richment and provided access to food (RM1.(E).SQC.; SDS
Ltd., Witham, UK) and water ad libitum throughout in an
environment of 20–24°C, 45–65% humidity and a 12:12 h
light : dark period.
Canine behavioural studies were conducted in accor-
dance with good laboratory practice standards (US FDA Good
Laboratory Practice Regulations 21 CFR Part 58) under
contract by CIT Safety and Health Laboratories (Évreux,
France) in accordance with EU Directive 86/609/EEC and to
the authors’ experimental design. A total of 40 [20 male
(mean weight: 9.5 kg) and 20 female (mean weight: 7.8 kg)]
adult (8 months) beagle dogs (Marshall Farms, NY, USA) were
habituated for 2 weeks and maintained at 20°C, 30–70%
humidity and a 12 h:12 h light : dark period in individual ken-
nels containing wood shavings (SICSA, Leon, France) and
provided free access to water plus ~300 g·day1 pelleted diet
(125 C3; SAFE, Augy, France). At the end of each behavioural
study, animals were humanely killed 24 h after the ﬁnal treat-
ment, using an appropriate method, as described below. Adult,
male C57BL/6 mice (n = 12), chickens (n = 12) and
Wistar–Han rats (n = 6) were obtained from Charles River Ltd
(Harlow, UK) and humanely killed in accordance with the UK
Animals (Scientiﬁc Procedures) Act 1986 and associated guide-
lines for the humane use of experimental animals and approved
by theUniversity of ReadingAnimalWelfare and Ethical Review
Body, to provide brain tissue for use in radioligand binding as-
says. Male beagle and male human cerebellae were supplied by
Charles River (UK) and Asterand Bioscience (Herts, UK),
respectively, and stored at 80°C until use. No distinct ethical
approval was required for the use of beagle or human tissue
since each was obtained from a licensed supplier.
Drugs and formulation
Standardized cannabis extracts (1.08:1 ratio of THC and CBD)
were supplied by GW Research Ltd (river, UK). The extract’s
composition complied with the US Food and Drug Adminis-
tration guidelines for botanical drug products.
Experimental design
Rat behavioural experiment. Rats were randomly allocated into
three groups. One group received low-dose (1.08 mg·kg1
THC + 1 mg·kg1 CBD in sesame oil; n = 25), while another
received high-dose (40.5 mg·kg1 THC + 37.5 mg·kg1 CBD in
sesame oil; n = 25) cannabis extract. The dose levels used in
rats were designed to lead to reported effective plasma
B J Whalley et al.
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concentrations (Deiana et al., 2012). A third group received
vehicle (sesame oil; n = 19). Drugs (or vehicle) were
administered once daily via p.o. gavage for 13 weeks (constant
dose volume = 10 mL·kg1 based on weekly animal weights.
Five animals per group were humanely killed by a schedule 1
method (e.g. overdose of anaesthetic followed by cervical
dislocation) at the end of each of day 2 and weeks 4, 8 and 13
for bioanalyte assessment and assessment of CB1R function.
Canine behavioural experiment. Dogs were randomized to
ﬁve groups each containing eight animals (four males and
four females) that received, via p.o. gavage daily, vehicle
(ethanol (sufﬁcient quantity), propylene glycol 50% v.v-1
and peppermint oil 0.05% v.v-1), sham treatment (puriﬁed
water), low-dose (2.7 mg·kg1 THC + 2.5 mg·kg1 CBD),
intermediate-dose (13.5 mg·kg1 THC + 12.5 mg·kg1 CBD)
or high-dose (27 mg·kg1 THC + 25 mg·kg1 CBD) cannabis
extract treatment for 56 weeks (up to 4 weeks
habituation + 52 weeks steady-state treatment). Habituation
to treatment in the intermediate- and high-dose groups was
as follows: high dose (doses expressed as mg·kg1·day1
THC/CBD): 5.4/5.0 (days 1–44), 8.1/7.5 (days 5–9), 10.8/10.0
(days 10–14), 13.5/12.5 (days 15–19), 16.2/15.0 (days 20–24)
and 21.6/20.0 (days 25–28); intermediate dose: 2.7/2.5 (days
10–14), 5.4/5.0 (days 15 to 19), 8.1/7.5 (days 20–24) and
10.8/10.0 (days 25–28). We believe that this is the ﬁrst study
to investigate the effects of prolonged cannabis extract
exposure on seizures in dogs; dose levels were selected on the
basis of the results of a previous internal study in dogs with a
similar route of administration and similar dose levels,
which resulted in good systemic exposure via p.o. gavage
administration. While acute cannabis intoxication in dogs
has not been reported to cause seizures, there is some
suggestion that longer-term, higher-dose cannabis may do so
(Fitzgerald et al., 2013); therefore, we tested the effects over a
52 week period in dogs to ensure maximum possibility of
detecting cannabis extract-induced seizure activity. On
completion of the treatment or treatment-free period, all
surviving dogs were anaesthetized by an i.v. injection of
thiopental sodium and killed by exsanguination.
Collection of behavioural and telemetry
measures
In rats, a subgroup (vehicle: n = 4; low dose: n = 10; high dose:
n = 10) was assessed by researchers trained to identify, code
and discriminate between convulsive behaviours according
to conventionally used rodent welfare criteria (Wolfensohn
& Lloyd, 2013). Behaviours associated with generalized
seizures in rodents included tonic or clonic convulsions,
myoclonic jerk, forelimb paddling, forelimb clonus, forelimb
ﬂickering, popping (involuntary movement characterized by
repeated and typically rhythmic jumping and/or twitching
that can range from stationary hiccough-like movements to
vigorous jumping) (Mastropaolo et al., 2004), wet dog shakes,
tremor, twitching and chewing (Luttjohann et al., 2009).
Behaviours not typically associated with seizure: piloer-
ection, ptosis, digit biting, increased grooming, increased
scratching, mouth rubbing, behavioural arrest, fascicula-
tions, writhing, licking, salivation, hind limb extension,
head searching, hunched posture and exophthalmos. Since
THC-induced convulsions in rodents have been suggested
to be associated with the act of drug administration and/or
handling (Chan et al., 1996; NTP, 1996), rats were observed
undisturbed in the home cage for at least 5 min and for a fur-
ther 5 min after removal from the home cage before ﬁnal ob-
servation for at least 10 min after treatment had been
administered each day. Behaviours were grouped into two
categories: ‘acute’ (during the 10 min observation period fol-
lowing daily dosing) and ‘persistent’ (during the 10 min in
the home cage prior to daily treatment). The subgroup of rats
was obtained with F40-EET (DSI, New Brighton, MN, USA) te-
lemetry transmitters and electrocorticography (EEG) elec-
trodes already surgically implanted by Charles River
(Cambridge, UK). Electrodes comprised two subcranial
(dural) wires (frontal cortex AP +4.7 mm and ML 0.5 mm;
parietal cortex AP 3.8 mm and ML 3.0 mm, c.f. bregma),
and EEG data were collected for 22 h periods on each of 10
pre-speciﬁed days during the study (day 1 plus 1 day from
each of the following day pairs: 28/29, 35/36, 42/43, 56/57,
63/64, 70/71, 77/78, 84/85 and 90/91). No animals exhibited
unusual EEG activity in recordings taken during the 22 h
prior to ﬁrst treatment. Full details of EEG recording and sig-
nal processing approaches are described in the Supporting
Information.
Dogs were examined for mortality, signs of morbidity and
conventional clinical signs, including seizure behaviour,
twice daily throughout the study period.
Analysis of drug and metabolite levels
In rats, terminal venous blood (~0.5 mL) was obtained into a
heparin-containing polypropylene tube. Samples were mixed
for ~2 min, placed on ice, centrifuged (~2300 g, 4°C, 10 min)
within 30 min of collection and plasma stored in polypropyl-
ene tubes (20°C) until analysis. Each rat brain was rapidly
removed after death, cerebrum and cerebellum separated,
ﬂash frozen in liquid nitrogen and stored at 80°C. Venous
canine blood was sampled immediately prior to the animals
being killed in heparin-containing polypropylene tubes, cen-
trifuged (~2300 × g, 4°C, 10 min) and plasma stored in
polypropylene tubes at 20°C until analysis. Prior to analysis,
rodent (cerebellum only) and canine brain samples were
homogenized (Lysing Matrix D, MP Biomedical, Santa Ana,
California, USA) inmethanol and water (20:80 v.v-1) on ice using
a FastPrep (MP Biomedical) for ~60 s. Plasma (rat and dog) and
brain (rat) concentrations of THC, 11-OH-THC (Lemberger et al.,
1973) and CBD were determined, while plasma and brain con-
centrations of 6-hydroxy-CBD (6-OH-CBD) and 7-hydroxy-CBD
(7-OH-CBD) were also determined for rats, using UPLC-MS/MS
in all cases. Details of sample preparation and analysis are
included in the Supporting Information.
Radioligand binding
Detailed methodology for membrane preparation, [3H]-
SR1416717A saturation binding and GTPγS assays are
included in the Supporting Information. Membranes were
prepared from all cerebellae tissue used in the rat cannabis
extract treatment study; cerebellae tissue was used due to
bioanalyte levels being measured from cerebellae tissue in
these experiments and also due to high CB1 receptor
expression in rat cerebellum (Tsou et al., 1998). Standardized
cerebellar membrane preparations were also produced from
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male treatment-naïve C57BL/6J mice, chickens, Wistar–Han
rats, beagles and humans, also due to uniformly high CB1
recepor expression in cerebellar tissue across different mam-
malian species (Herkenham et al., 1990).
Saturation binding. The high afﬁnity antagonist [3H]-
SR1416717A (pKD 8.9–10, Alexander et al., 2017) was used,
assays were conducted in triplicate and three separate assays
were performed in each case. Radioactivity bound to cortex
membranes was quantiﬁed in disintegrations per minute
(dpm) before conversion to pmol·mg1. Analyses of
saturation binding data were conducted by non-linear
regression and ﬁtted to a one-binding site model to
determine the equilibrium KD (nM) and the maximal
number of binding sites Bmax (pmol·mg
1) using GraphPad
Prism software (GraphPad Software Inc., San Diego, CA,
USA).
[35S]-GTPγS binding assay. Assays were carried out in
triplicate, and three separate assays were performed in each
case. [35S]-GTPγS assay data were analysed using GraphPad
Prism. Concentration–response data were analysed using a
sigmoidal concentration–response model or linear regression
and compared using an F-test to select the appropriate
model. On this basis, best ﬁts to sigmoidal curves were
obtained with Hill slopes of unity, and no other constraints
applied. For curves showing no concentration-related
increases, linear regression was performed to determine if
slopes differed signiﬁcantly from zero. Values for EC50 were
derived from ﬁtted curves to mean data and Emax
expressed as percentage over basal or as percentage of the
mean maximal response following stimulation with the
highest concentration of the CB1 receptor full agonist,
WIN55,212-2 (10 μM). In experiments that examined the
effects of agonist stimulation in membranes prepared from
drug-treated animals and where mathematically possible,
data were ﬁtted to an operational model of ligand binding
(Black & Leff, 1983). Here, dpm were plotted, and the
tissue-agonist combination that yielded the largest
maximal stimulation was identiﬁed (i.e. WIN55,212-2
responses in vehicle-treated animals). The magnitude of
this highest maximal stimulation was used to scale
(0–100%) other tissue–agonist combinations. Prior to
scaling, basal stimulation was subtracted to constrain the
bottom of all derived curves to zero. In experiments that
examined differences between tissues from different
species using [35S]-GTPγS assays, prior to normalization,
data expressed as dpm were plotted in order to assess
any differences arising from expression and sensitivity
levels.
We produce a descriptive representation of the overall
proﬁle of THC-mediated CB1 receptor-mediated signalling
for each species (which we term the ‘eCB signalling foot-
print’) by normalizing (i) CB1 receptor expression (Bmax;
‘Expression’), (ii) basal G-protein turnover (dpm at the lowest
concentration of THC; ‘Basal’), (iii) sensitivity (EC50;
‘Sensitivity’) and (iv) activation (Emax; ‘Extent’) in response
to agonist stimulation, to the species with the highest value
for each measure.
Drugs. The following drugs were used: WIN55,212-2
(Tocris, Bristol, UK), [3H]-SR141716A and [35S]-GTPγS (GE
Healthcare, Chalfont St. Giles, Buckinghamshire, UK).
Randomization and blinding
Canine and rat behavioural studies and canine and rat
bioanalyte studies were conducted in accordance with
industry-standard good laboratory practice and additional
regulatory compliances as detailed above. Such compliance
ensures randomization of animals to each speciﬁed group
and appropriate blinding. For canine studies (CIT Safety
and Health Laboratories), a computerized randomization
procedure (using validated CIT software) was used. For rat
studies (Covance, Leeds, UK), animals were identiﬁed by
numbered tail marks and electronic ID; prior to the start of
the study, animals were randomly allocated to treatment
groups and individually tattooed by Charles River. In all
cases, operators were blinded to treatment. For in vitro bind-
ing studies, membrane preparations were randomly selected
by the operator; here, all parameters stated are measured nu-
merical values, which were not inﬂuenced by any observer-
related bias, and therefore, blinding was not considered to
be necessary.
Statistics
Data subjected to statistical comparisons did not violate as-
sumptions of normality (D’Agostino–Pearson omnibus test)
and are expressed as mean ± SEM. Group sizes for data sub-
jected to statistical comparisons were designed on the basis
of power calculations to identify differences between canna-
bis extract doses. Groups were compared by one- or two-way
ANOVA tests followed by Tukey’s post hoc tests as appropri-
ate using GraphPad Prism; post hoc tests were run only if F
achieved P < 0.05 and there was no signiﬁcant variance in
homogeneity. A variance–covariance principal component
analysis (PCA) of animal behavioural data was undertaken
using XLSTAT (New York, NY, USA); this analysis used daily
data normalized to the proportion of animals per group
exhibiting any given behaviour before calculation of a
group mean value for each behaviour for the 13 week treat-
ment period. Interpretation of the variance described by the
ﬁrst and second principal components was undertaken by
examination of the squared cosines and percentage contri-
butions of each variable to the total variance (see
Supporting Information). In accordance with the journal
policy, P < 0.05 was reported as level of signiﬁcance. The
data and statistical analysis comply with the recommenda-
tions on experimental design and analysis in pharmacology
(Curtis et al., 2015).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data
from the IUPHAR/BPS Guide to PHARMACOLOGY
(Harding et al., 2018), and are permanently archived
in the Concise Guide to PHARMACOLOGY 2017/18
(Alexander et al., 2017).
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Results
Effects of cannabis extract treatment on plasma
and brain cannabinoid bioanalyte levels
Concentrations of THC and its active metabolite, 11-OH-
THC, plus CBD and its metabolites, 6-OH-CBD and 7-OH-
CBD, in plasma and cortical homogenate from rats that
received 13 weeks’ vehicle, low-dose (1.08 mg·kg1
THC and 1 mg·kg1 CBD) or high-dose (40.5 mg·kg1 THC
and 37.5 mg·kg1 CBD) cannabis extract treatment via p.o.
gavage were measured (Table 1). With the exception of 6-
OH-CBD, which was not detected in any samples from any
group, all other bioanalytes were identiﬁed in at least one
group of rats that received low- or high-dose cannabis extract
treatment. One-way ANOVA tests revealed a signiﬁcant effect
of group upon THC, 11-OH-THC, CBD and 7-OH-CBD con-
centrations in brain and plasma, which arose from a signiﬁ-
cant increase in level of each cannabinoid and metabolite
present in the high-dose, in comparison with low-dose, can-
nabis extract-treated groups (Table 1). THC, 11-OH-THC and
CBD (but not 6-OH-CBD and 7-OH-CBD) were present at de-
tectable levels in the low-dose group.
Concentrations of THC, 11-OH-THC and CBD in canine
plasma samples from sham, vehicle, low-dose (2.7 mg·kg1
THC and 2.5 mg·kg1 CBD), intermediate-dose (13.5 mg·kg1
THC and 12.5 mg·kg1 CBD) and high-dose (27 mg·kg1 THC
and 25 mg·kg1 CBD) cannabis extract-treated groups were
measured (Table 1). All bioanalytes were identiﬁed in at least
one group that received low-, intermediate- or high-dose
treatment; one-way ANOVA tests revealed a signiﬁcant effect
of group upon THC, 11-OH-THC and CBD concentrations in
plasma, which arose from signiﬁcant increases in cannabi-
noid levels in the intermediate- and high-dose, in compari-
son with low-dose, cannabis extract-treated groups. THC,
11-OH-THC and CBD were detectable in the low-dose group
in canines. No evidence for any cannabinoids was found in
sham- or vehicle-treated samples. Overall, relative to dose ad-
ministered, the THC plasma concentration was higher in rats
than dogs; although the active metabolite 11-OH-THC, and
CBD, was higher in dogs. Together, these data demonstrate
that p.o. administration of higher dose cannabis extracts is
effective in producing increased physiologically relevant
levels of major cannabinoids and metabolites and that
bioanalyte proﬁles differed between rats and dogs. These
data provided a validated basis to study dose-dependency
of seizure induction by cannabis extracts and permit quali-
tative comparisons between species.
Effects of cannabis extract treatment upon
behaviours in rats and dogs
Low-dose cannabis extract treatment produced acute
(observed during the 10 min period following daily dosing)
behavioural signs in rats from day 17, which continued
throughout the 13 week treatment (Figure 1). The most
frequently observed acute effects (descending order of
magnitude of the median proportion exhibiting a behaviour
during the treatment period) were mouth rubbing, forelimb
paddling, increased scratching, wet dog shakes, forelimb
ﬂickering, increased grooming, ptosis and chewing; less fre-
quent effects (median incidence of zero but with non-zero
interquartile range) were writhing and salivation (Table 2
and Supporting Information Table S1). Persistent (observed
during the 10 min prior to daily treatment) behavioural ef-
fects of low-dose cannabis extract in rats occurred on day 18
and continued throughout the 13 week treatment (Figure 2).
Here, the most frequently observed effects were increased
grooming, increased scratching and ptosis; less frequent ef-
fects were wet dog shakes, forelimb ﬂickering, forelimb pad-
dling and writhing (Table 2 and Supporting Information
Table S1). In the high-dose group, acute behavioural signs
in rats were observed from day 17 and continued throughout
the 13 week treatment (Figure 1). The most frequently ob-
served acute effects were forelimb paddling, mouth rubbing,
ptosis, increased scratching, piloerection, wet dog shakes,
forelimb ﬂickering, chewing, salivation and increased
grooming; less frequently, behavioural arrest and twitch were
observed (Table 2 and Supporting Information Table S1). The
ﬁrst persistent behavioural effects of high-dose treatment in
rats were seen from day 18 and also continued throughout
the 13 week treatment (Figure 2). Here, the most frequently
observed behaviours were increased scratching, increased
grooming, piloerection and wet dog shakes; less frequently,
ptosis and forelimb paddling were observed (Table 2 and
Supporting Information Table S1). No vehicle-treated ani-
mals exhibited any of the behaviours coded (results from
this group are omitted for clarity). The mean values for the
normalized incidence of each of the behaviours exhibited
by cannabis extract-treated rats, prior to and after treatment
administration (Figures 1 and 2 and Supporting Information
Table S2), were subjected to PCA. The ﬁrst three components
accounted for 100% of the variability of which 90.1 and
8.4% of variability was accounted for by the ﬁrst and second
principal components respectively. Mouth rubbing and fore-
limb paddling behaviours made a cumulative contribution
of 68.3% to the ﬁrst principal component with correspond-
ing squared cosine values >0.9 (Supporting Information
Table S2). A biplot of the ﬁrst two principal components
revealed a positive correlation between ‘acute’ behaviours
and the ﬁrst principal component, while the converse
applied to ‘persistent’ behaviours (Figure 3A); the ﬁrst
principal component therefore represents behaviours associ-
ated with administration of the drug. The second principal
component positively correlated with high-dose cannabis
extract treatment, indicating that this measure is dose
related. A circle plot of these data (Figure 3B) revealed that
several behaviours were strongly associated with acute expo-
sure to cannabis extract, irrespective of dose. The circle plot
revealed that several behaviour characteristics of generalized
seizures such as popping, convulsion, myoclonic jerk and
twitch were positively correlated with the high-dose group,
while the converse applied to increased grooming and
writhing (Figure 3B). Notably, myoclonic jerk and convul-
sion were independent, while popping, increased grooming
and writhing were negatively associated, with acute mea-
surement of behaviour. The remaining behaviours showed
no overt dose-dependency.
In dogs, no behaviours associated with seizures were
seen. There were seven unscheduled deaths across all groups
except the sham control and low-dose groups, which oc-
curred as follows: vehicle group (1 female; day 361),
intermediate group (3 male; days 31, 315 and 339) and high
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group (3 male; days 14, 30 and 221). The mortality pattern
showed no measurable dose relationship, and post-mortem
examination attributed mortality to clinical complications
following reﬂux and aspiration of stomach contents
and/or formulated treatment into the lungs rather than a
drug-related effect. During the habituation period, ptyalism
was observed in vehicle, intermediate- and high-dose
groups, which continued in the steady-state period, during
which time this sign was also noted in the low dose and,
to the least extent, sham groups (Table 3). Incidence of pty-
alism was not dose related and was attributed to vehicle ex-
cipients. Other clinical signs seen during habituation
occurred predominantly in the high-dose group and could
be assigned to two categories: (i) hypoactivity, ataxia and
tremor (from day 2) and (ii) abdominal breathing,
tachypnoea, lateral recumbency, reﬂux at dosing, vomiting,
soft or liquid faeces and dehydration (from day 18). During
the steady-state treatment period, dogs exhibited clinical
signs (Table 3) divided into four categories: (i) dose-related
neurological signs (ataxia, tremor and hypoactivity) oc-
curred primarily in cannabis extract-treated groups but with
decreased frequency compared with the habituation phase;
(ii) thin appearance manifested without clear treatment,
time, dose or sex relationship, and all dogs consumed
≥75% of food offered each day; (iii) gastrointestinal signs,
occurred primarily in cannabis extract-treated groups with
dose-related incidence; (iv) oro-respiratory signs (ptyalism,
dyspnoea and abdominal breathing). Ptyalism occurred in
all groups at steady state but was highest in cannabis
extract-treated groups, suggesting attribution to the excipi-
ents. Overall, in dogs, cannabis extract, even at the highest
dose tested, caused limited neurological, gastrointestinal
and oro-respiratory behavioural signs. Most importantly,
convulsive episodes were never observed in dogs from any
group, and repeated drug treatment was well tolerated.
EEG and seizure analysis in rats
Visually identiﬁed motor convulsions (Racine stage: ≥3;
Jones et al., 2010, 2012) occurred in 80% (8/10) of rats in
the high-dose cannabis extract group; by contrast, motor
convulsions were never observed in the low-dose or vehicle
treatment groups. A total of 24 motor convulsions were ob-
served in the high-dose group where average time from start
of treatment to ﬁrst convulsion was 50.5 ± 7.5 days; convul-
sions continued until the end of the study (Supporting
Figure 1
Temporal representation of acute behaviours in rats (n = 10 per group) 10 min after daily p.o. low-dose [1.08 mg·kg1 THC (Δ9-THC) + 1 mg·kg1
CBD] or high-dose (40.5 mg·kg1 THC + 37.5 mg·kg1 CBD) cannabis extract treatment for 13 weeks. Behavioural events associated with gen-
eralized seizures in rodents are highlighted in bold.
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Figure 2
Temporal representation of persistent behaviours in rats (n = 10 per group) ~23 h after daily p.o. administration of low-dose [1.08 mg·kg1 THC-
(Δ9-THC)+ 1 mg·kg1 CBD] or high-dose (40.5 mg·kg1 THC + 37.5 mg·kg1 CBD) cannabis extract treatment for 13 weeks. Behavioural events
associated with generalized seizures in rodents are highlighted in bold.
Figure 3
(A) Biplot of the ﬁrst two principal components (F1 and F2) derived from daily behavioural data (see Methods). Positive values of the ﬁrst
principal component were positively correlated with observations made in the period shortly after dosing (acute), irrespective of dose,
whereas the converse applied to observations made prior to daily treatment (persistent). Positive values of the second principal component
were positively correlated with observations made in animals that received high-dose (40.5 mg·kg1 THC + 37.5 mg·kg1 CBD; n = 10)
cannabis extract, irrespective of dose timing, whereas the converse applied to observations made in animals that had received low-dose
(1.08 mg·kg1 THC + 1 mg·kg1 CBD; n = 10) cannabis extract. (B) Correlation plot showing association of behaviours with the ﬁrst
and second principal components.
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Information Table S3). Of the 24 convulsive events, 17 oc-
curred during drug administration or the subsequent obser-
vation period, while the remaining 7 events occurred prior
to animal handling or were detected after review of video
data when EEG analysis revealed an epileptiform event.
EEG recordings from the high-dose group revealed 18
events exhibiting epileptiform activity (handling-related
artefacts rendered 2/18 recordings unsuitable for presenta-
tion and are omitted) (Figure 4 and Supporting Information
Table S3). Video data or direct observation showed that
15/18 (~80%) of epileptiform events were accompanied by
a motor convulsion (Racine stage: ≥3) from which each an-
imal recovered without intervention. By contrast, only one
animal (out of 10) from the low-dose group exhibited an
epileptiform event (Figure 5A and Supporting Information
Table S3); although the electrophysiological proﬁle of this
event was consistent with events seen the high-dose group
(Figure 4 vs. Figure 5A, B), video data from this one animal
did not reveal an accompanying motor convulsion. All epi-
leptiform events exhibited rhythmic, large amplitude, sharp
wave activity of increasing amplitude prior to spontaneous
termination (c.f. pretreatment baseline activity; Figures 4
and 5A, B) that persisted for 55 ± 7.6 s (n = 17). Spectro-
grams showed that all epileptiform activities induced by
high-dose and the single low-dose example dominated the
1–20 Hz range where accompanying measures of power
spectrum density (PSD) revealed 2–7 Hz peaks [Figure 5B,
panel b, C (inset)]. Mean PSD conﬁrmed that epileptiform
activity induced by high-dose cannabis extract exhibited a
signal proﬁle (Figure 5C) with peaks present at 2, 3 and
4.5 Hz, consistent with primary generalized seizures
(Luttjohann et al., 2009). Together, these data suggest that
Figure 4
Epileptiform events recorded via EEG in rats treated with high-dose (40.5 mg·kg1 THC + 37.5 mg·kg1 CBD) cannabis extract (Supporting Infor-
mation Table S2). Each panel shows the EEG recording of the complete epileptiform event (top left), a shorter section of the event during the pe-
riod of greatest amplitude activity represented on an extended timescale (bottom left) and a spectrographic representation of each event [right; x-
axis: time (s); y-axis: frequency (Hz); and colour bar: power (dB·mV2)]. * Indicates occurrence of a seizure during drug administration or within
10 min thereafter. ¥ Indicates an epileptiform event detected via EEG that was accompanied by a motor convulsion.
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sustained high-dose treatment reliably caused motor
convulsions, subserved by spontaneous epileptiform activ-
ity in rat.
Coded behaviours were re-examined, and those consis-
tent with primary generalized seizure in rats were pooled be-
fore calculation of cumulative incidence (Figure 5D, panel a)
to reveal more frequent occurrence of acute than persistent
seizure-related behaviours in both low-dose and high-dose
treatment groups. Irrespective of these acute effects, seizure-
related behaviours occurredmore frequently in the high-dose
than the low-dose group (Figure 3B). Further, when behav-
iours consistent with seizure (bold in Figures 1 and 2) were
examined (Figure 5D, panel b), event incidence reached
maximum levels at 40–50 days treatment before declining,
irrespective of dose or time of observation (i.e. ‘acute’ or
‘persistent’). Some behaviours are not typically associated
with seizure in rodents (not bold in Figures 1 and 2);
nevertheless, their cumulative incidence (Figure 5D, panel
c) and temporal distribution (Figure 5D, panel d) were similar
to those of seizure-associated behaviours (Figure 5D, panels
a, b), suggesting a common underlying aetiology. These
data suggest that behaviour signs in rat are increased during
or immediately after handling/drug administration and that
such variations should be considered when testing for drug
effects in rodents.
Effects of cannabis extract treatment on CB1
receptor expression and G-protein turnover in rat
cerebellar membranes
CB1 receptor densitywas investigated inmembranes from cer-
ebellar brain tissue of all rats used in the above behavioural
studies obtained at four time points (2 days and weeks 4, 8
and 13) during treatment with vehicle, low-dose or high-dose
cannabis extract by saturation binding assay using the CB1
Figure 5
(A) EEG recordings from a rat treated with low-dose (1.08 mg·kg1 THC + 1 mg·kg1 CBD) cannabis extract during (panels a, b) pretreatment
baseline and (panels c, d) an epileptiform event. In panel c, * and ** show areas reproduced in panels d, e respectively. (B, panel a) Spectro-
graphic representation of [A, panel c, right; x-axis: time (s); y-axis: frequency (Hz); and colour bar: power (dB·mV2)] and (panel b) resulting
PSD. (C) Mean (black) ± SEM (red dotted) PSD of epileptiform events recorded via EEG from animals treated with high-dose (40.5 mg·kg1
THC + 37.5 mg·kg1 CBD; n = 10) cannabis extract. Inset shows overlay of individual PSD plots per event per animal. (D) (panel a) Cumulative
incidence and (panel b) temporal distribution of coded behaviours associated with seizures in animals (see Methods) treated with low- or high-
dose cannabis extracts. (panel c) Cumulative incidence and (panel d) temporal distribution of coded behaviours not associated with seizures in
animals (see Methods) treated with low- or high-dose cannabis extracts.
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receptor antagonist, [3H]-SR141716A, and expressed as Bmax
(Figure 6A, panels a–d, B and Table 4). [35S]-GTPγS binding
was also examined in the same rat brain cerebellar membrane
preparations from the 13 week treatment groups to assess CB1
receptor sensitivity to the partial agonist, THC, and the full
agonist, WIN55,212-2 (Figure 6C, panels a–d). Here, in
membranes from vehicle-treated animals, THC had a proﬁle
consistent with partial agonism (EC50: 69 nM; Emax: 27%),
Figure 6
Saturation binding of [3H]-SR141716A to cerebellar membranes from rats treated with vehicle, low-dose (1.08mg·kg1 THC + 1mg·kg1 CBD) or
high-dose (40.5 mg·kg1 THC + 37.5 mg·kg1 CBD) cannabis extracts for (i) 2 days, (ii) 4, (iii) 8 and (iv) 13 weeks. (B) Temporal proﬁle of Bmax
(pmol·mg1) derived from (A, panels a–d). (C) Log concentration–response best-ﬁt curves for stimulation of [35S]-GTPγS binding by THC and
WIN55 212-2 in cerebellar membranes for week 13 data shown in (A). Data expressed as%maximal stimulation by 10 μMWIN55,212-2 in vehicle
group membranes ﬁtted to an operational model of ligand binding (THC/high dose lack of response prevented valid curve derivation, and a sub-
jectively assessed non-linear ﬁt was employed). (panel d) Overlay of best ﬁt curves derived from panels a–c. W, WIN55,212-2; T, THC; C, control
(vehicle); L, low dose; H, high dose. No ‘T–H” curve presented. (D) (panel a) Saturation binding of [3H]-SR141716A to human, chicken, dog,
mouse and rat cerebellar membranes. (panel b) Log concentration–response curves for stimulation of [35S]-GTPγS binding (dpm) by THC in cer-
ebellar membranes from species indicated. (panel c) Log concentration–response curves for stimulation of [35S]-GTPγS binding (normalized) by
THC in cerebellar membranes from the species indicated. (E) (panel a) Equivalent (to D, panel b) curves for THC (Δ9-THC)+ CBD (1.08:1.00).
(panel b) Equivalent (to D, panel c) curves for THC + CBD (1.08:1.00). Data obtained from chicken, dog and human membrane samples were
not amenable to sigmoidal curve ﬁtting; here, subjective best ﬁts are shown, but EC50 not calculated. Concentration expressed as THC. (panel
c) Equivalent (to D, panel b) curves for CBD. (panel d) Equivalent (to D, panel c) curves for CBD. Data obtained were not amenable to sigmoidal
curve ﬁtting; here, subjective best ﬁts are shown but EC50 not calculated. (F) Radar plot showing CB1 receptor (‘Expression’; D, panel a), basal G-
protein turnover (‘Basal’; D, panel b) and sensitivity to and extent of agonist stimulation (‘Sensitivity’ and ‘Extent’; D, panel c) by species based
upon (A–E) scaled as percentage of the species exhibiting the highest value for a given measure. With the exception of (F), all values shown are
mean ± SEM; n = 3 experiments of three technical replicates in all cases.
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while WIN55,212-2 exhibited a comparable EC50 but with a
numerically greater Emax (EC50: 68 nM; Emax: 99%), consistent
with its proﬁle as a full agonist. In tissue from the low-dose-
treated group, responses to THC (EC50: 40 nM; Emax: 31%)
and WIN55,212-2 (EC50: 53 nM; Emax: 93%) were similar
to those seen in the vehicle-treated group; this was in clear
contrast to the high-dose group, where the response to
WIN55,212-2 (EC50: 84 nM; Emax: 44%) was attenuated,
and the THC response so markedly attenuated as to be too
small for an EC50 value to be accurately derived, and Emax
was depressed to ~7%. These results indicate that prolonged
cannabis extract treatment clearly attenuates CB1 receptor-
mediated G-protein signalling in rats with more profound ef-
fects in the high-dose cannabis group.
Inter-species differences in CB1 receptor
expression and effects of cannabinoids on
G-protein turnover in cerebellar membranes
CB1 receptor density was ﬁrst investigated by saturation bind-
ing assay using [3H]-SR141716A in membranes from
treatment-naïvemouse, rat, chicken, dog and human cerebel-
lar tissue (Figure 6D, panel a, and Table 5). [35S]-GTPγS
binding assays were also conducted using the same
membrane preparations to examine the effects of THC, THC-
+ CBD (in the same 1:08:1.00 ratio used in in vivo rat study
above) and CBD alone. For THC-alone datasets, a range of
basal activity (measured as actual dpm in the presence of
the lowest concentration of agonist) between species was ob-
served (Figure 6D, panel b). Following data normalization
(Figure 6D, panel c), rats, mice and chickens were shown to
have similar EC50 values, while humans showed the highest
and dogs the lowest EC50; however, it is possible to have
greater sensitivity but less consequence of activation, and
THC Emax was numerically higher for chickens, rats and dogs
than mice and humans (Table 5). For THC plus CBD, while a
range of basal activity was again evident (Figure 6E, panel a),
normalized treatment-induced increases in stimulation were
much more limited in comparison with THC alone (Figure 6
E, panel b, vs. D, panel c) and, for the human, dog andmouse,
ﬁts could not be derived (Table 5). For CBD alone, a range of
basal activity was again seen, and approximately negligible
[35S]-GTPγS binding was observed (Figure 6E, panels c, d),
consistent with a lack of CB1 receptor agonist effect, as re-
ported by us previously (Jones et al., 2010).
Table 4
[3H]-SR141716A saturation binding in cannabis extract-treated rats
Treatment
group
Treatment period
2 days 4 weeks 8 weeks 13 weeks
Bmax
(pmol·mg1) KD
Bmax
(pmol·mg1) KD
Bmax
(pmol·mg1) KD
Bmax
(pmol·mg1) KD
Vehicle 1.86 ± 0.13 1.19 ± 0.25 1.64 ± 0.12 0.93 ± 0.23 1.39 ± 0.08 1.43 ± 0.23 1.31 ± 0.06 1.18 ± 0.16
Low dose 2.23 ± 0.13 0.90 ± 0.17 1.21 ± 0.06 0.74 ± 0.13 1.06 ± 0.05 0.90 ± 0.13 0.97 ± 0.07 0.88 ± 0.20
High dose 1.11 ± 0.17 0.95 ± 0.47 1.10 ± 0.11 1.54 ± 0.45 0.44 ± 0.07 0.39 ± 0.25 0.45 ± 0.05 0.90 ± 0.31
Bmax (pmol·mg
1) and KD values for CB1 receptor expression using saturation binding of [
3H]-SR141716A to cerebellar membranes from animals that
had been treated with vehicle, low-dose (1.08 mg·kg1 THC + 1mg·kg1 CBD) or high-dose (40.5 mg·kg1 THC + 37.5 mg·kg1 CBD) cannabis extract
for 2 days and 4, 8 and 13 weeks (Figure 6A, panels a–d, B). Values shown are mean ± SEM; experiments in triplicate in three separate preparations.
Table 5
Species-speciﬁc responses in radioligand binding assays
Species
Saturation binding
[35S]-GTPγS assays
THC THC + CBD (1.08:1.00)
Bmax (pmol·mg
1) KD (nM) EC50 (nM) Emax (% over basal) EC50 (nM) Emax (% over basal)
Mouse 3.94 ± 0.38 3.18 ± 0.59 76 9.4 ± 5.9 N/A N/A
Rat 1.91 ± 0.04 1.14 ± 0.13 58 29.0 ± 1.2 52 20.8 ± 0.9
Chicken 1.80 ± 0.09 2.21 ± 0.98 97 37.0 ± 4.5 72 23.9 ± 2.1
Dog 1.01 ± 0.11 0.97 ± 0.36 281 28.8 ± 4.1 N/A N/A
Human 0.30 ± 0.11 1.03 ± 0.18 17 6.6 ± 6.1 N/A N/A
Bmax (pmol·mg
1) and KD (nM) derived from saturation binding of [
3H]-SR141716A (Figure 6D, panel a) and EC50 (nM) (derived from a single ﬁt to
group data) and Emax (% over basal) for THC (Figure 6D, panel c) and THC + CBD (1.08:1.00 ratio) (Figure 6E, panel b) derived from [
35S]-GTPγS assays
conducted using membranes prepared from treatment-naïve cerebellae. EC50 for THC + CBD (derived from a single ﬁt to group data) is expressed
against concentration of THC present in the assay. CBD alone was also examined in all species but revealed approximately negligible [35S]-GTPγS
binding (Figure 6E, panel d), as was also the case for THC + CBD in human, dog and mouse membranes. In these cases, EC50 and Emax could not be
conﬁdently estimated and are omitted and recorded as N/A. Values shown are mean ± SEM; experiments in triplicate in three separate preparations.
N/A, not available.
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To best assess our supporting in vitro data, we combined
these observations to provide an overall proﬁle of THC-
mediated, CB1 receptor-mediated signalling for each species
(Figure 6F) by normalizing CB1 receptor expression (Bmax;
‘Expression’) (Figure 6D, panel a), basal G-protein turnover
(dpm at the lowest concentration of THC; ‘Basal’; Figure 6D,
panel b) and sensitivity (EC50; ‘Sensitivity’) and activation
(Emax; ‘Extent’) in response to agonist stimulation
(Figure 6D, panel c), to the species with the highest value
for each measure. We term this measure the ‘eCB signalling
footprint’; as discussed more fully below, together these
data suggest species-speciﬁc differences in this proﬁle with
the highest value in the rat, intermediate values in the
mouse and chicken and comparably lower values for
humans and dogs.
Discussion
We show that motor convulsions in rats, but not dog, can
be induced by sustained treatment with cannabis extract
in a dose-related manner; effects of higher dose cannabis ex-
tract in rats are subserved by primary, generalized epilepti-
form discharges in vivo and are associated with impaired
CB1 receptor-mediated signalling. Furthermore, in vitro pro-
ﬁling experiments suggest that eCB signalling plays a more
dominant role in rat, a species susceptible to cannabis
extract-induced seizures, than in dog, a species resistant to
such seizures.
Prolonged cannabis extract treatment causes
spontaneous convulsions due to primary,
generalized epileptiform events and associated
deficits in CB1 receptor signalling in rats
In behavioural analysis of cannabis extract-treated rats,
behaviours classically associated with primary generalized
seizures, including myoclonic jerk and convulsions
(Mastropaolo et al., 2004; Luttjohann et al., 2009), were posi-
tively correlated with high-dose treatment; by contrast, rats
exhibited limited peripheral symptoms following such treat-
ment. Sustained cannabis extract exposure induced sponta-
neous convulsions in rats. Here, the frequency of convulsive
episodes induced at the higher dose was lower than that re-
ported in a previous study for comparable doses of THC (ad-
ministered alone) in rats (Chan et al., 1996). Since the same
route and administration frequency, plus similar formula-
tion, were used, we suggest that CBD in our cannabis prep-
arations may exert anticonvulsant effects (Rosenberg et al.,
2015) that limited, but did not prevent, proconvulsant ef-
fects of THC. We also propose that measurements of acute
cannabis extract effects in rats reﬂect handling and/or
drug-related stress effects; thus, when measured within
10 min of drug administration, several behaviours were ex-
acerbated, and similar behavioural responses have been
noted previously (Chan et al., 1996; NTP, 1996). As such,
for measures of acute cannabis extract effects, it may be dif-
ﬁcult to determine the relative inﬂuences of (i) interactions
between handling and pharmacological effects of cannabi-
noids already present, (ii) acute responses to formulation
palatability and/or gavage and (iii) rising plasma concentra-
tions of cannabinoids after dosing (phytocannabinoid Tmax
in rodents (p.o.): ~30–60 min (Deiana et al., 2012), upon
positively correlated seizure-associated behaviours in rats.
Persistent behavioural symptoms only manifested after
several days’ sustained treatment in both rat and dog.
Phytocannabinoid p.o. bioavailability is known to be poor,
but lipophilicity is high, meaning that repeated administra-
tion for several days is needed to saturate the fat compart-
ment and thereafter achieve higher plasma concentrations
(Sharma et al., 2012). Moreover, adaptive responses by sig-
nalling systems (e.g. protein trafﬁcking) targeted by
phytocannabinoids may require several days to manifest
(Silva et al., 2016).
We demonstrate for the ﬁrst time that cannabis extract-
induced convulsions in rats are subserved by spontaneous
epileptiform discharges. Such seizures in rodents are
characterized by EEG abnormalities such as 6–10 Hz
spike–wave discharges (behavioural arrest), 5–9 Hz spiking
(facial clonus) and rising and falling frequency 2–3 to
6–7 Hz high-amplitude events (clonic or tonic–clonic
seizures) (Luttjohann et al., 2009). We routinely observed
these associated behaviours in rat; moreover, power spectra
revealed peaks in the equivalent frequency bands. Of further
interest was that high-dose cannabis extract reliably pro-
duced such seizures; however, only one rat with low-dose
treatment demonstrated epileptiform activity, and this was
not accompanied with a motor convulsion.
Our radioligand binding results in cannabis extract-
treated rats demonstrate that THC effects on the endogenous
cannabinoid system signalling were clearly impaired in a
dose-related manner. Thus, among the 13 week treatment
groups, high-dose cannabis extract treatment caused CB1
receptor-mediated G-protein signalling to be severely attenu-
ated such that we were unable to ﬁt curves to derive any EC50
value and Emax was clearly depressed. Overall, we propose
that prolonged high-dose cannabis extracts functionally im-
pairs eCB system signalling and that this mechanism under-
lies the reported exacerbation of seizures in rat. It was of
interest that the incidence of seizure-associated behaviours
in rats diminished from day ~50; these data are consistent
with a long-term suppression of seizures, as reported from
day ~500 in rats treated with THC for 2 years (Chan et al.,
1996). Temporal proﬁles of this sort are distinct from that as-
sociated with kindling, a commonly used model of human
epilepsy (Bertram, 2007), and, we suggest, are manifestations
of an adaptive response to a down-regulated eCB system to
restore physiological seizure threshold.
Inter-species differences in susceptibility to
cannabis extract-induced convulsions
The predictive validity of non-human models for cannabi-
noid effects is generally regarded as inconsistent; moreover,
therapeutic cannabis beneﬁts are predicted from animal
models of anxiety, depression, schizophrenia and pain; con-
versely, evidence supports exacerbation of mental illness
and contraindication of CB1 receptor ligands in people with
a history of seizures (Hill et al., 2012). We therefore investi-
gated the effects of different cannabis extracts on behaviours
(including seizure activity) in an alternative (canine) species
to rat. Of interest is that dogs (including beagles) are highly
susceptible to epilepsy (Heske et al., 2014). Cannabinoid
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plasma concentrations detected were consistent with ranges
associated with human recreational and medicinal use in
both the rat and dog (Lee et al., 2015). Here, we report that,
despite this general sensitivity, sustained cannabis extract
exposure for up to 52 weeks in dogs is not a precipitating
factor for seizures; although we cannot fully rule out the
effects at higher cannabis extract doses than tested here, we
demonstrate clear species differences in terms of lack of
cannabis extract-induced seizures and limited effects on
CNS behavioural measures in dogs. Brain cannabinoid con-
centration levels were not measured in dogs; however, we rea-
son that plasma cannabinoid concentration is proportional
to brain concentration [as phytocannabinnoids readily pene-
trate the mammalian blood–brain barrier (Deiana et al., 2012)
and there is no a priori reason to believe that the canine
blood–brain barrier differentially affects this parameter]
allowing us to extrapolate from plasma data. Dogs receiving
intermediate- and high-dose cannabis extract treatment also
received a habituation phase to avoid potentially toxic effects
in this higher species; however, no seizures were seen in this
period. Moreover, by directly comparing cannabinoid plasma
concentrations, it is clear that despite low-dose cannabis
extract-treated rats having THC plasma levels ~70-fold lower
than high-dose-treated dogs, we saw more pronounced CNS
behavioural effects in rats and were still able to report
seizure-related behaviours and (albeit rare) epileptiform
events, which were never seen dog, even at high dose. It is
also of note that, relative to dose administered, the plasma
concentration of the active metabolite 11-OH-THC, which
has reportedly higher in vivo potency than THC (Lemberger
et al., 1973), was higher in dog than rat. Overall, these data
are consistent with THC pharmacokinetic differences not be-
ing able to explain fully these differences in seizure behav-
iour. A pertinent difference was that plasma CBD levels were
also consistently higher in the dog than rat; thus, our data
are also consistent with increased CBD levels in dogs acting
to ameliorate the proconvulsant effects of long-term THC
seen in rats, as reported recently for CBD prevention of
chronic THC-induced long-term behavioural abnormalities
in mice (Murphy et al., 2017).
Results from our supporting description of eCB signalling
footprint between species suggest a proﬁle whereby
rat> chicken>mouse > human = dog. Of interest is that this
proﬁle was highest in rat, a species in which cannabis extracts
induced reliable epileptiform convulsions and caused clear
signalling down-regulation, but was lowest in dog, a species
in which epileptiform convulsions did not occur. These data
also support previous meta-analysis across different studies
whereby THC was reported to show differential inhibitory
constant (Ki) values between human versus rat CB1 receptors
(McPartland et al., 2007). Our data further conﬁrms a lack of
CB1 receptor signalling by CBD alone and, consistent with
previous reports (McPartland et al., 2015), that the presence
of higher concentrations of CBD reduced THC-induced ef-
fects in our [35S]-GTPγS assays. The latter may reﬂect an atten-
uation of THC’s effects by CBD, and these data are further
consistent with the lack of seizure-related behaviour seen in
dogs, as discussed above; alternatively, this may reﬂect CBD
negative allosteric modulation (Laprairie et al., 2015) and/or
non-speciﬁc effects due to cannabinoid lipophilicity. Taken
together, this description suggests that seizure activity in rats
reﬂects THC proconvulsant effects and that the eCB system
plays a greater role in the physiology of species susceptible
to THC/cannabis-induced seizures than species where
seizures are not seen.
In terms of potential mechanism of action, CB1 receptor-
mediated signalling acts primarily to inhibit neurotransmit-
ter release from excitatory and inhibitory presynapses in the
CNS (Diana & Marty, 2004). We propose that eCB signalling
plays a greater role in regulating neurotransmitter release in
species susceptible to cannabis-induced seizure; for example,
a THC-induced down-regulation of eCB signalling may lead
to a net loss of CB1 receptor-mediated inhibition of excitatory
neurotransmitter release in these species to allow seizures to
manifest. It is possible that the lower eCB signalling footprint
we identiﬁed in dogs is reﬂected by a resistance of CB1 recep-
tors to down-regulation or, for example, that CB1 receptors
are more weakly coupled to inhibition of presynaptic neuro-
transmitter release.
Conclusions and future perspectives
Our data suggest that choice of model species to study
cannabis-induced convulsions may have important implica-
tions in extrapolation to the human condition. We reveal
clear differences in seizure behaviour and in cannabinoid
plasma concentrations in response to cannabis extract con-
sumption in rats versus dogs and suggest differences in eCB
signalling in rats compared with dogs and humans (and to a
lesser extent to mice and chickens). In humans, the reported
THC : CBD plasma concentration ratio following p.o. (Guy &
Robson, 2003) or oromucosal (Karschner et al., 2011) admin-
istration of similar cannabis extracts better approximates
values for rats, rather than dogs, reported here. When set be-
side our ﬁndings that prolonged cannabis extract treatment
induced seizures in rats but not dogs, our study indicates a
poor predictive validity for animal models when assessing
cannabis-mediated effects in humans. Thus, we propose a
number of important caveats that must be considered in this
context; speciﬁcally, irrespective of species, responses to
acute exposure to eCB system modulators are unlikely to
reﬂect responses to sustained exposure, the latter potentially
due to a propensity for CB1 receptor down-regulation.
Further, the eCB system may play a more dominant role in
the physiology of lower-order species. As such, assertions of
therapeutic beneﬁts or risks from rodent data may be dimin-
ished in clinical conditions. It is therefore important that an
investigation of comparative eCB system physiology between
species is undertaken to determine model predictive validity.
As such, greater use of acutely excised human tissue and char-
acterization of the eCB system in human stem cell-derived
cultures may address these problems and better predict
potential risks associated with an emerging new wave of
cannabinoid therapeutics.
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Table S1 Incidence of behaviours in rats (n=10 per group)
observed immediately after (10 min; ‘acute’) or ~23 hours af-
ter (‘persistent’) daily oral administration of low dose (1.08
mg kg-1 Δ9-THC + 1 mg kg-1 CBD) or high dose (40.5 mg kg-1
Δ9-THC + 37.5 mg kg-1 CBD) cannabis extract for 13 weeks
that exhibited a median and IQR of zero. Behavioural events
conventionally associated with generalised seizures in ro-
dents are highlighted in bold.
Table S2 Table showing squared cosine and percentage con-
tribution of each measured behaviour following variance-co-
variance principal component analysis applied to all
behaviours recorded in low dose (1.08 mg kg-1 Δ9-THC + 1
mg kg-1 CBD) and high dose (40.5 mg kg-1 Δ9-THC + 37.5
mg kg-1 CBD) cannabis extract treated animals. Behaviours
highlighted in bold show those conventionally associated
with primary generalised seizures in rodents (see also: Figures
1 & 2). Squared cosine values shown in bold highlight the
principal component in which the value exhibited its highest
value. Table also shows factor values for each observation for
the ﬁrst two principal components (F1 and F2).
Table S3 Incidence of all convulsive motor events and/or
epileptiform events exhibited in rats treated with low dose
(1.08 mg kg-1 Δ9-THC plus 1 mg kg-1 CBD) or high dose
(40.5 mg kg-1 Δ9-THC plus 37.5 mg kg-1 CBD) cannabis ex-
tract for 13 weeks. Note that in some case, accompanying
EEG recordings (see Figure ) showed (*) multiple, discrete,
epileptiform events during a single motor convulsion and
(**) animal handling or severity of motor convulsion that
prevented acquisition of valid EEG data.
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